Non-faecalis and non-faecium enterococci are an occasional cause of bacteremia, and some cases of infective endocarditis caused by these pathogens have been reported. However, the rate of infective endocarditis in non-faecalis and non-faecium enterococcal bacteremia is still undetermined. We compared the clinical features and the rate of infective endocarditis of 70 cases of non-faecalis and non-faecium enterococcal bacteremia with those of 65 cases of Enterococcus faecalis bacteremia. Non-faecalis and non-faecium enterococcal bacteremia was more frequently associated with biliary tract infection and polymicrobial bacteremia, and was less frequently associated with infective endocarditis, than was E. faecalis bacteremia (57% vs. 28%, p＜0.01; 47% vs. 31%, p=0.05; 1% vs. 14%, p＜0.01, respectively).
INTRODUCTION
Enterococcus faecalis and Enterococcus faecium are significant human pathogens. Hence, the clinical features and outcomes of infections caused by these organisms have been well described. 1, 2 However, few clinical studies have been conducted on infections caused by non-faecalis and non-faecium enterococci such as Enterococcus avium, Enterococcus hirae, Enterococcus durans, Enterococcus gallinarum, Enterococcus casseliflavus, and Enterococcus flavescens, [3] [4] [5] [6] although these are also encountered as significant human pathogens. Among the non-faecalis and non-faecium enterococci, E. gallinarum, E. casseliflavus, and E. flavescens possessing the vanC gene are characterized by motility and intrinsic low-level resistance to vancomycin (the VanC phenotype). These species have caused concern, because treatment failure or inducible vancomycin resistance is possible during vancomycin therapy. 3, 5, 6 Enterococci are the third common etiologic agent of infective endocarditis, accounting for 11% of cases. 7 E. faecalis is a common cause of infective endocarditis, and ＞3% of cases of E. faecalis bacteremia have infective endocarditis. In contrast, only ＜1% of cases of E. faecium bacteremia have infective endocarditis. Some cases of infective endocarditis caused by non-faecalis and non-faecium enterococci have also been reported. [8] [9] [10] [11] [12] [13] However, the rate of infective endocarditis in non-faecalis and non-faecium enterococcal bacteremia is still undetermined. The aim of this study was to compare the clinical features and the rate of infective endocarditis of bacteremia due to non-faecalis and non-faecium enterococci with those of E. faecalis bacteremia.
MATERIALS AND METHODS

Patients
The electronic medical records of all patients with positive blood cultures for enterococci between January 1999 and August 2003 at Seoul National University Hospital (Seoul, Republic of Korea) were retrospectively reviewed. Underlying diseases, the primary site of bacteremia, comorbid or predisposing conditions, antibiotic resistance, and treatment outcomes in patients with non-faecalis and non-faecium enterococcal bacteremia were compared with those in patients with E. faecalis bacteremia. Appropriate antibiotic treatment was defined as the use of one or more active antibiotics to which the organism was susceptible in vitro within 5 days of the date on which a positive blood culture was obtained.
14 Antibiotics considered active included penicillin, ampicillin, piperacillin, vancomycin, teicopla- 
Microbiological tests
Enterococcus species were identified on the basis of 6.5% NaCl tolerance, bile-esculin hydrolysis, and growth rate at 45 o C. Species were identified from the results obtained with the Vitek system (bioMérieux, Marcy l'Etoile, France) and by tests for motility, yellow pigmentation, and methyl-α-D-glucopyranoside. 16, 17 Antibiotic susceptibilities were determined by the disk diffusion method, following the recommendations of the Clinical and Laboratory Standards Institute. 18 The vancomycin and teicoplanin minimal inhibitory concentration (MIC) was determined by Etest Ⓡ (AB BIODISK, Solna, Sweden) according to the manufacturer's manual. VanC phenotype enterococci were defined as enterococcal isolates with intrinsic lowlevel resistance to vancomycin (MICs 2-32 μg/ml) and susceptibility to teicoplanin. 
Statistical analysis
Categorical variables were compared by using the Fisher's exact test or the Pearson χ 2 test, as appropriate, and continuous variables were compared by using the MannWhitney test or Student's t test. All tests of significance were 2-tailed, and p≤0.05 was considered to be significant. Statistical analyses of the data were performed by using SPSS for Windows (ver. 12.0; SPSS Inc., Chicago, IL).
RESULTS
Enterococcus species in blood isolates
We identified 292 cases with enterococcal bacteremia during the study period. One hundred fifty (51.4%) were caused by E. faecium and 65 (22.3%) by E. faecalis. Seventy (24.0%) were caused by non-faecalis and non-faecium enterococci; 23 (7.8%) by E. avium, 20 (6.8%) by E. gallinarum, 19 (6.5%) by E. casseliflavus, 7 (2.4%) by E. hirae, and 1 (0.3%) by E. durans. The species responsible for seven (2.4%) isolates could not be identified. The patients from whom the isolates could not be identified were excluded from the analysis. None of patients with non-faecalis and non-faecium enterococcal bacteremia were clustered in time or place of occurrence.
Clinical features and the rates of infective endocarditis
in non-faecalis and non-faecium enterococcal bacteremia The clinical features of 135 patients with bacteremia caused by non-faecalis and non-faecium enterococci or E. faecalis are shown in Table 1 . Compared with cases of E. faecalis bacteremia, underlying biliary disease and biliary tract infections were significantly more common in cases of non-faecalis and non-faecium enterococcal bacteremia. Polymicrobial bacteremia was also more common in cases of non-faecalis and non-faecium enterococcal bacteremia. E. coli (n=11), Pseudomonas species (n=6), and Klebsiella species (n=4) were the predominant blood co-isolates from cases of non-faecalis and non-faecium enterococci. Valvular heart disease and infective endocarditis were significantly less common in non-faecalis and non-faecium enterococcal bacteremia than in E. faecalis bacteremia (Table  1) . However, 14-day mortality was not significantly different between patients with non-faecalis and non-faecium enterococcal bacteremia and patients with E. faecalis bacteremia (16% vs. 15%, p=0.93; Table 2 ).
Clinical features of patients with vanC phenotype en-
terococci We compared the clinical features, outcomes, and microbiological data for bacteremia caused by VanC phenotype enterococci with those of bacteremia caused by non-faecalis and non-faecium enterococci without the VanC phenotype (Table 3) . Biliary tract infection was the most common infection site in both groups (48% vs. 64%). No significant differences were apparent in underlying disease, infection site, or other clinical characteristics between these two 
Expressed as mean (±SD). ‡
Persistent bacteremia was defined as the isolation of enterococci in blood cultures obtained from peripheral veins on ≥5 consecutive days despite appropriate antibiotic administration.
§ Expressed as number of deaths/number of patients followed up (%). APACHE: acute physiology and chronic health evaluation, MIC: minimal inhibitory concentration, ND: not done.
groups. There was also no significant difference in outcome. Although five of the patients with bacteremia caused by VanC phenotype enterococci had undergone vancomycin therapy, no breakthrough or recurrent bacteremia was observed.
DISCUSSION
In this study, we showed that cases of non-faecalis and non-faecium enterococcal bacteremia were more likely to have biliary tract infection and polymicrobial bacteremia and were less likely to have infective endocarditis than were cases of E. faecalis bacteremia. In the present study, biliary tract infection was significantly more common in non-faecalis and non-faecium enterococcal bacteremia than in E. faecalis bacteremia, in agreement with previous studies. 2, 3 The proportion of polymicrobial bacteremia (47%) in our study was similar to the findings of previous studies: 44.6% to 50%.
2,4,5
The anatomical site of infection should be taken into account in treating enterococcal infection, because the appropriate treatment strategy differs for different sites. In cases of endocarditis or meningitis, combination therapy with a cell-wall active agent plus an aminoglycoside should be used. 1, 20 However, in cases of enterococcal bacteremia without endocarditis or meningitis, there was no statistically significant difference in outcome between monotherapy and combination therapy in a number of studies. [21] [22] [23] [24] [25] It has been described that infective endocarditis is significantly more common in E. faecalis bacteremia than in E. faecium bacteremia. 26 Previous reports showed that non-faecalis and non-faecium enterococci also have sufficient virulence to cause infective endocarditis on native heart valves in patients without predisposing valvular heart diseases. [9] [10] [11] [12] However, the rate of infective endocarditis in non-faecalis and non-faecium enterococcal bacteremia had never been evaluated. In our study, we demonstrated for the first time that the rate of infective endocarditis in non-faecalis and non-faecium enterococcal bacteremia was only about 1%, and it was significantly lower than that in E. faecalis bacteremia. Our data suggest that routine echocardiography tests or aminoglycoside combination therapy is not necessary in patients with non-faecalis and non-faecium enterococcal bacteremia, unless the patient has suspicious signs of infective endocarditis such as persistent bacteremia, predisposing heart conditions, cardiac murmur, or metastatic infection. Some workers have suggested that bacteremia due to VanC phenotype enterococci is associated with a low risk of mortality 2 ; however, no comparative study was ever performed on the matter. In our comparative study, however, we found that the mortality in patients with bacteremia caused by VanC phenotype enterococci was not lower than that in patients with bacteremia caused by non-VanC non-faecalis and non-faecium enterococci or E. faecalis. VanC is known to be chromosomally encoded and constitutively expressed. However, the VanC phenotype may be inducible in some strains. 27, 28 Treatment failure and breakthrough bacteremia during vancomycin therapy have been reported even though the isolates were of the VanC phenotype susceptible to vancomycin. 4, 5 However, this phenomenon was not observed in our study. The low-level vancomycin resistance of these organisms had little influence on treatment outcomes in our study. Some studies reported high rates of vancomycin resistance (MIC ＞32 μg/ml) in clinical isolates of VanC phenotype enterococci, 2,3 whereas others did not. 4, 5 In our study, vancomycin resistance was not observed in the VanC phenotype enterococci, which is consistent with the latter studies. The present data have some limitations. First, we used only biochemical methods, not a molecular method for the species level identification of enterococci. Seven (2.4%) of the isolates were not species identified, and therefore infections caused by these isolates were not included in the analysis. Second, this was a single-center study and factors such as the rate of referrals or surgery for complex disorders could have impacted the results. In conclusion, compared with patients with E. faecalis bacteremia, patients with non-faecalis and non-faecium enterococcal bacteremia were more likely to have biliary tract infection and polymicrobial bacteremia and were less likely to have infective endocarditis. The outcome of nonfaecalis and non-faecium enterococcal bacteremia was not different from that of E. faecalis bacteremia. VanC phenotype did not affect mortality in patients with enterococcal bacteremia.
